Trial Profile
A randomized, double-blind, double-dummy, placebo-controlled, parallel group study to assess the efficacy and safety of 48 weeks of once daily treatment of orally inhaled BI 1744 CL (5 µg [2 actuations of 2.5 µg] and 10 µg [2 actuations of 5 µg ]) delivered by Respimat Inhaler, and 48 weeks of twice daily Foradil (12 µg) delivered by the Aerolizer Inhaler, in patients with Chronic Obstructive Pulmonary Disease (COPD)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 21 Jan 2022
Price :
$35
*
At a glance
- Drugs Olodaterol (Primary) ; Formoterol
- Indications Chronic obstructive pulmonary disease
- Focus Pharmacogenomic; Registrational; Therapeutic Use
- Sponsors Boehringer Ingelheim; Boehringer Ingelheim Pharmaceuticals
- 24 May 2017 Results assessing long-term safety profile of olodaterol from NCT00793624 and NCT00796653 trials presented at the 113th International Conference of the American Thoracic Society
- 11 Sep 2013 Pooled safety analysis results presented at the 23rd Annual Congress of the European Respiratory Society.
- 11 Sep 2013 Pooled analysis assessing change in respiratory symptoms presented at the 23rd Annual Congress of the European Respiratory Society.